ISELIN, N.J., June 2, 2016 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasivecontinuous glucose monitoring (CGM) and associated technologies, today announced that it is in the final stage of selecting a Clinical Research Organization (CRO) for the development of a comprehensive regulatory and clinical strategy for its CGM system.
"Identifying the right CRO partner is critical to our success. We are currently in discussions to determine the organization best suited to develop and execute our strategy and to provide consultation as we progress with product development," said Scott W. Hollander, Echo's President and CEO. "Based on our progress, I am excited to begin plans for the future clinical trial of our NextGen system."
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:Christine H. OlimpioDirector, Investor Relations and Corporate Communications (732) 201-4189
Connect With Us:- Visit our website at www.echotx.com- Follow us on Twitter at www.twitter.com/echotx- Join us on Facebook at www.facebook.com/echotx
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/echo-therapeutics-in-final-stage-of-clinical-research-organization-cro-selection-300278477.html
SOURCE Echo Therapeutics, Inc.
Subscribe to our Free Newsletters!
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...
Intermittent fasting is a complete or partial abstinence from food and caloric drinks for a ...View All